Maryland PDAB Selects Six Drugs for Cost Review

Start
During its meeting on May 20, Maryland’s Prescription Drug Affordability Board (PDAB) unanimously voted to conduct cost reviews on six of eight products it was considering (see table below). Maryland is the third PDAB, following Colorado and Oregon, to select drugs for a cost or affordability review….
By: Manatt, Phelps & Phillips, LLP
Previous Story

Malouf Companies Notifies Consumers of February 2024 Data Breach

Next Story

Paging Cybersecurity: Healthcare Providers Need to Make a “Change” to Protect Themselves, and Their Patients, Against Cyberattacks